Granisetron

Granisetron

SCHEMBL33433

CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2.Cl

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HTR3A

The experimentally established mechanism targets of Granisetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR3A known ✓ P46098 12/20 0.98
HTR3E A5X5Y0 1/20 0.98
SLC22A2 O15244 1/20 0.98
HTR3B O95264 1/20 0.98
CHRNB2 P17787 1/20 0.98
CHRNA3 P32297 1/20 0.98
CHRNA4 P43681 1/20 0.98
KCNH2 Q12809 1/20 0.98
HTR3D Q70Z44 1/20 0.98
HTR3C Q8WXA8 1/20 0.98
SLC47A1 Q96FL8 1/20 0.98
ALDH1A1 P00352 1/20 0.89
CYP3A4 P08684 1/20 0.89
TSHR P16473 1/20 0.89
MAPK1 P28482 1/20 0.89
HSD17B10 Q99714 1/20 0.89
KDM4E B2RXH2 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Granisetron SCHEMBL34179 1.00 HTR3A (0.98) HTR3AHTR3ESLC22A2HTR3BCHRNB2
Granisetron SCHEMBL34177 1.00 HTR3A (0.98) HTR3AHTR3ESLC22A2HTR3BCHRNB2
Granisetron SCHEMBL30773918 1.00 HTR3A (0.98) HTR3AHTR3ESLC22A2HTR3BCHRNB2
Granisetron SCHEMBL5067161 0.99 HTR3A (0.96) HTR3AHTR3ESLC22A2HTR3BCHRNB2
Granisetron SCHEMBL445223 0.99 HTR3A (1.00) HTR3AHTR3ESLC22A2HTR3BCHRNB2
Granisetron SCHEMBL16642163 0.99 HTR3A (1.00) HTR3AHTR3ESLC22A2HTR3BCHRNB2
Granisetron SCHEMBL13660190 0.99 HTR3A (1.00) HTR3AHTR3ESLC22A2HTR3BCHRNB2
Granisetron SCHEMBL4890 0.99 HTR3A (1.00) HTR3AHTR3ESLC22A2HTR3BCHRNB2
Granisetron SCHEMBL4109977 0.99 HTR3A (1.00) HTR3AHTR3ESLC22A2HTR3BCHRNB2
Granisetron SCHEMBL34178 0.99 HTR3A (1.00) HTR3AHTR3ESLC22A2HTR3BCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4848 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260076872-A1 POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME SIO2 MEDICAL PRODUCTS LLC (US) 2026-03-19 US claimed
US-20260069687-A1 THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER ASTELLAS PHARMA INC (JP) 2026-03-12 US claimed
US-20250242092-A1 SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS SIO2 MEDICAL PRODUCTS INC (US) 2025-07-31 US claimed
EP-3893913-B1 TRANSFERRIN RECEPTOR TARGETING PEPTIDES FRED HUTCHINSON CANCER CENTER (US) 2025-03-26 EP claimed
US-12257371-B2 SiOx barrier for pharmaceutical package and coating process SIO2 MEDICAL PRODUCTS, LLC (US) 2025-03-25 US claimed
US-20250059301-A1 Fusion Protein Construct NORTHWESTERN UNIVERSITY 2025-02-20 US claimed
US-20240390364-A1 Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions REID CHRISTOPHER BRIAN (US) 2024-11-28 US claimed
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO claimed
US-20240282425-A1 AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS LOW GORDON KEITH (US) 2024-08-22 US claimed
US-20240074944-A1 PECVD COATED PHARMACEUTICAL PACKAGING OAKTREE FUND ADMINISTRATION, LLC 2024-03-07 US claimed
US-20010036474-A1 Endo-N-(9- methyl-9-azabicyclo[3.3.1] non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride JAMES SUSAN (GB) 2001-11-01 US claimed
US-6308714-B1 Ultrasound enhanced chemotherapy CORAJE, INC. 2001-10-30 US claimed
US-6294548-B1 MIXTURE OF INDAZOLE, PRESERVATIVE AND BENZYL ALCOHOL ANTI-EMETIC, PARTICULARLY IN THE TREATMENT OF CYTOTOXIC AGENT INDUCED EMESIS, IN U.S. HOFFMANN-LA ROCHE INC. 2001-09-25 US claimed
US-20010020029-A1 New multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H- indazole-3-carboxamide hydrochloride SMITHKLINE BEECHAM P.L.C. 2001-09-06 US claimed
WO-2001054667-A1 ELECTROSPUN PHARMACEUTICAL COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 2001-08-02 WO claimed
US-20010005722-A1 endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1h-indazole-3-carboxamide hydrochloride HOFFMAN-LA ROCHE INC. 2001-06-28 US claimed
WO-2000076500-A2 COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION RESPIRATORIUS AB (SE) 2000-12-21 WO claimed
EP-0200444-B1 AZABICYCLONONYL-INDAZOLE-CARBOXAMIDE HAVING 5-HT ANTAGONIST ACTIVITY BEECHAM GROUP PLC (GB) 1992-11-11 EP claimed
US-5098909-A 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF COUGH AND BRONCHOCONSTRICTION BEECHAM GROUP, P.L.C. (GB) 1992-03-24 US claimed
US-4886808-A Indazolyl carboxylic acid amides useful for treating migraine clusters headache, trigeminal neuralgia or emesis BEECHAM GROUP P.L.C. (GB) 1989-12-12 US claimed